LPTX - CONSENSUS CO - Leap Therapeutics, Inc.

Ensuring a strict temperature regime during drug delivery guarantees that patients receive therapy in a timely manner. Leap Therapeutics, Inc. (LPTX) relies on patent protection for antibodies used in the treatment of gastric cancer, which, combined with the use of combination therapies, strengthens margins. The brand's high authority in immuno-oncology is confirmed by clinical successes, and this chart of the market valuation on GURU.Markets is fixed at .

This metric aggregates expert target prices, reflecting the asset's expected value based on the analysis of future cash flows and operational successes. The stagnation of the consensus price target indicates a lack of new growth drivers, which is critical for Leap Therapeutics, Inc. (LPTX) due to high capital burn on clinical trials and reliance on external financing, creating a risk of a sharp price correction.